Table 1 Baseline characteristics.

From: First insights and future research perspectives from the sarcoidosis registry at the Medical University of Vienna

Baseline characteristics

Total

Male

Female

p -value

Clinical characteristics

 Patients (n, %)

199

85 (42.5)

109 (57.5)

0.0036

 Age (yrs, mean, SD)

52 (13)

52 (12)

55 (14)

0.2408

 Age at time of diagnosis (yrs, median, IQR)

46 (36; 55)

40 (35; 50)

50 (37; 57)

0.0601

 BMI (kg/m², median, IQR)

27.76 (24.14; 31.64)

28.7 (26.05; 31.62)

25.63 (23.05; 32.39)

0.5915

 Smoker (%)

89 (44.5)

50 (63.8)

38 (34.8)

0.0006

 Pack years (yrs, median, IQR)

0 (0; 10)

10 (0; 19)

0 (0; 7)

0.4975

Comorbidities

 Allergies (n, %)

40 (20.0)

20 (24.1)

20 (18.3)

0.2739

 Arterial hypertension (n, %)

9 (4.5)

4 (4.8)

5 (4.6)

0.9399

 COPD (n, %)

5 (2.5)

2 (2.4)

3 (1.8)

0.8826

 Asthma (n, %)

11 (5.5)

5 (6.0)

6 (5.5)

0.4445

 Cancer (n, %)

23 (11.5)

6 (7.2)

17 (15.6)

0.0769

 Diabetes mellitus type 2 (n, %)

15 (7.5)

7 (8.2)

8 (7.0)

0.7475

 Pulmonary hypertension (n, %)

4 (2.0)

2 (2.4)

2 (1.8)

0.7824

Pulmonary function test (PFT)

 FEV1 predicted (%, median, IQR)

91.5 (77.0; 101.0)

88.0 (74.0; 101.0)

81.5 (67.5; 93.0)

0.0506

 FEV1 (mL, median, IQR)

2790 (2228 ;3558)

3710 (2580; 4410)

2070 (1530; 2735)

< 0.001

 FEV1/FVC ratio (median, IQR)

0.97 (0.92; 1.03)

0.96 (0.92; 1.04)

0.96 (0.92; 1.00)

0.9999

 TLC (mL, median, IQR)

5595 (4865; 6903)

7145 (5700; 7780)

4830 (4100; 5390)

< 0.001

 KCO/SB (%, median, IQR)

89.3 (77.6; 101.3)

98.7 (88.9; 106.2)

82.9 (74.8; 94.3)

< 0.001

 DLCO/VA (%, median, IQR)

88.6 (79.4; 95.5)

86.3 (69.5; 90.3)

87.8 (74.6; 93.4)

0.2512

Clinical features

 Arthralgia (n, %)

4 (2.0)

2 (2.4)

2 (1.8)

 

 Chest pain (n, %)

3 (1.5)

2 (2.4)

1 (0.9)

 

 Cough (n, %)

8 (4.0)

3 (3.5)

5 (4.4)

 

 Dyspnea (n, %)

25 (12.5)

15 (17.6)

10 (8.8)

 

 Fatigue (n, %)

0 (0.0)

0 (0.0)

0 (0.0)

 

 Myalgia (n, %)

5 (2.5)

2 (2.4)

3 (2.6)

 

 Palpitations (n, %)

11 (5.5)

7 (8.3)

4 (3.5)

 
  1. Significance level p<0,05 are in bold.
  2. Baseline characteristics of the registry population at time of inclusion; group comparisons were assessed using t-tests for metric parameters and chi-square tests for categorical parameters; BMI: body mass index; COPD: chronic obstructive pulmonary disease; FEV1: forced expiratory volume in 1 s; TLC: total lung capacity; DLCO/VA: diffusing capacity of the lung for carbon monoxide divided by alveolar volume; KCO: carbon monoxide transfer coefficient; yrs: years.
Back to article page